One of its recently launched products, the G-NiiB Immune Kids SIM03, was introduced to the Singapore market in October last year through platforms such as Shopee, but the company has also been selling it at major retailers Watsons and Guardian since February this year. We plan to make it available. .
The product is designed for children aged 1 to 5 years and is said to be undergoing clinical research at the Department of Pediatrics at the Chinese University of Hong Kong (CUHK).
It debuted in Hong Kong in March last year.
This product claims to improve gastrointestinal discomfort, skin strength, and skin healing.
talk to NutraIngredients – Asia, Jonathan Wong, regional business manager at GenieBiome, said most existing products for eczema are applied topically but do not address the underlying problem.
The product is therefore designed to improve the body’s ability to regulate inflammation, which has been identified as one of the causes behind eczema, Wong said.
“Most treatments are topical. If they don’t address the cause of the problem, the aim is to relieve the symptoms, so there are also products such as moisturizing creams and sometimes steroids to reduce itching.
“But we’ve established that eczema is partly due to inflammation. When you have inflammation in your body, it can lead to skin disease.
“We developed this product because we found that if you can improve or strengthen your gut health, you improve your ability to regulate inflammation.” he explained.
He said the synbiotic formulation, which consists of maltodextrin, oligosaccharides, xylitol as a prebiotic, a probiotic blend, calcium acetate, and zinc acetate, will be used over a three-month period for children aged 1 to 5 years. He said that it is being studied clinically in clinical research.
One of the findings was that SCORAD scores, an assessment tool that measures the extent and severity of atopic dermatitis/eczema, were reduced in children who took the supplement.
Based on SCORAD, all participants who had “moderate” eczema symptoms reported that their symptoms became “mild” after three months of supplementation.
50% of participants who had a “severe” condition also reported a “moderate” condition.
The lesion area, or area of the affected skin area, also decreased by 38.9% overall.
On average, there was a 53% improvement in quality of life, including itching, poor sleep, and interference with bathing, dressing, and sports activities.
Wong said the clinical results are expected to be published in an international journal this year.
Probiotics and colorectal cancer
Besides eczema, GenieBiome also launched another probiotic product, G-NiiB M3Xtra, to reduce bloating, diarrhea, and gastrointestinal discomfort.
At the same time, the “M3” in the product name refers to a group of bacteria that induce serious diseases in the intestine, that is, a group of bacteria that is associated with a high risk of colorectal cancer, adenoma, and adenoma recurrence. – Cancerous tumors.
Therefore, this product is also intended for people who have had adenomas removed, people who have a high risk of colorectal cancer due to family history, and patients who have been treated for colorectal cancer.
This formula is comprised of three Bifidobacterium strains and two Bifidobacterium strains already used in our flagship product, G-NiiB Immune Formula SIM01. thermophilusWong said the strain has been proven to reduce pathogenic bacteria by up to 80 percent and replenish missing beneficial bacteria.
Wong said the product was developed by comparing the gut microbiota of healthy people and colorectal cancer patients. From this, the company identified the good bacteria that patients lack and the bad bacteria that patients have in abundance.
he said that the two of them thermophilusThe bacterial strain used in this product has been shown in clinical practice to stimulate a “gelling effect” in the intestinal wall, preventing undigested food, endotoxins, and particles from entering the bloodstream and causing an inflammatory response. Masu.
The product was also launched online in Hong Kong and Singapore late last year.
Wong said that since its launch, sales of the company’s flagship product, G-NiiB Immune Formula SIM01, have rapidly caught up.
“The sales of the two products are at an almost 1:1 ratio.”he said.
He added that colorectal cancer is a common cancer in many countries, but it would be a long process for an adenoma to grow into a tumor. This means that it will take a long time before potential interventions are made to improve the situation.
“About 90% of cancers arise from adenomas, so if we can remove the adenoma and reduce the risk of adenoma growth, we can lower the risk. We have confirmed this and are now offering this formulation to help reduce your risk.” he said.
The formulation will also be tested in Singapore on people suffering from irritable bowel syndrome (IBS).
Market expansion
In addition to Singapore, the company is also prioritizing overseas expansion in Malaysia.
The company currently sells its products in Malaysia through cross-border e-commerce (CBEC) through Shopee and Lazada, but is considering registering its products for offline retail in the first quarter of this year.
The company also has a presence in China through CBEC and has begun expanding into Indonesia.